Post hoc analysis of three 6-week placebo-controlled trials (n=1,385) in acute schizophrenia: brexpiprazole 2–4 mg/day improved PSP functioning vs placebo in those with hostility (LSMD 2.82), without hostility and with agitation, but not significantly in those without agitation.
Secondary analysisn = 1,385
Citrome et al. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials